000			03833cam a2200445Mi 4500
988			_aSpringer_Medicine_2017
999			_c94885 _d94885 _x1
001			94885
003			ES-MaUEC
005			20230102112636.0
006			m o d
007			cr cnu---unuuu
008			161119t20162017sz ob 000 0 eng d
020			_a3319432966 _q(electronic bk.)
020			_a9783319432960 _q(electronic bk.)
020			_z331943294X
020			_z9783319432946 _q(print)
035			_a(OCoLC)963696106 _z(OCoLC)963351276
040			_aEBLCP _cEBLCP _dN$T _dIDEBK _dGW5XE _dOCLCQ _dUAB _dIOG _dESU _dZ5A _dJBG _dIAD _dICW _dICN _dOTZ _dYDX _dOCLCQ _dU3W _dMERUC _dES-MaUEC _bspa
050		4	_aRC662.18 _b2017 EB
100	1		_aFisher, Miles _9677282 _eautor
245	1	0	_aEssentials of SGLT2 inhibitors in diabetes _cMiles Fisher, Gerard McKay
264		1	_aCham _bAdis _c[2016]
264		4	_c2017
300			_a1 recurso en línea (77 páginas)
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
500			_aSpringerLink
504			_aIncluye referencias bibliográficas
505	0		_aBiographies; Contents; Editors; Contributors; Chapter 1: Overview of Type 2 Diabetes; 1.1 Epidemiology and Global Disease Burden; 1.2 Diagnostic Criteria for Diabetes; 1.3 Glucose Homeostasis; 1.4 Pathogenesis of Type 2 Diabetes; 1.5 Risk Factors for the Development of Diabetes; 1.6 Clinical Features of Diabetes; 1.7 Complications of Diabetes; References; Chapter 2: SGLT2 Inhibitors for Treating Diabetes; 2.1 Mode of Action and Clinical Pharmacology; 2.2 Drug Development and Major Clinical Trials; 2.2.1 Phlorizin; 2.2.2 Glycemic Effects of Dapagliflozin.
505	8		_a2.2.3 Glycemic Effects of Canagliflozin2.2.4 Glycemic Effects of Empagliflozin; 2.2.5 Glycemic Effects of SGLT2 Inhibitors: Where Are We Now?; 2.3 Effects of SGLT2 Inhibitors on Body Weight; 2.4 Effects of SGLT Inhibitors on Blood Pressure; 2.5 Adverse Effects and Safety; 2.5.1 Hypoglycemia with SGLT2 Inhibitors; 2.5.2 Genital Infections; 2.5.3 Volume Depletion; 2.5.4 Effects of SGLT2 Inhibitors on Lipids; 2.5.5 Effects on Renal Function; 2.5.6 Fractures; 2.6 Ketoacidosis; References; Chapter 3: Guidelines for the Treatment of Type 2 Diabetes Mellitus; 3.1 Introduction.
505	8		_a3.2 International Diabetes Federation Guidelines3.3 Joint American Diabetes Association and European Association for the Study of Diabetes Position Statement; 3.3.1 Update to the Joint ADA/EASD Position Statement; 3.4 Country Case Study: Developing Guidelines in the UK; 3.5 Conclusion; References; Chapter 4: Using SGLT2 Inhibitors in Special Populations; 4.1 Introduction; 4.2 SGLT2 Inhibitors in Patients with Cardiovascular Disease; 4.2.1 EMPA-REG OUTCOME; 4.2.2 Cardiovascular Trials with Other SGLT2 Inhibitors; 4.3 SGLT2 Inhibitors in Patients with Chronic Kidney Disease.
505	8		_a4.3.1 Cohort Analysis of Patients Treated with Canagliflozin4.3.2 Renoprotective Aspects of SGLT2 Inhibitors; 4.3.3 Renal Outcome Studies with SGLT2 Inhibitors; 4.4 SGLT2 Inhibitors in Older Patients with Type 2 Diabetes; 4.4.1 Dapagliflozin in Older Patients with Type 2 Diabetes; 4.4.2 Canagliflozin in Older Patients with Type 2 Diabetes; 4.5 SGLT2 Inhibitors in Type 1 Diabetes; 4.5.1 Empagliflozin in Type 1 Diabetes; 4.5.2 Dapaglifozin in Type 1 Diabetes; 4.5.3 Sotagliflozin in Type 1 Diabetes; 4.5.4 Future Prospects in Type 1 Diabetes; References.
588	0		_aVersión impresa
650		7	_9138582 _aDiabetes _2embne
700	1		_aMcKay, Gerard A. _9677283 _eautor
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-43296-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b02/2018 _dz _e- _zSI